arrow
G

Gina L. Mazza

Mayo Clinic
H指数:25
被引数:2,661

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Designing and Implementing Real World Patient Reported Outcomes (RW- PROs) - Emerging Recommendations: A Good Practices Report of an ISPOR Task Force

设计与实施真实世界患者报告结局(RW-PROs)——新兴建议:ISPOR工作组的一份良好实践报告

2026-03-180
PRE
ProAE: an R package for graphical tools and standardized analysis of patient-reported outcomes and adverse events data

ProAE:一个用于患者报告结局和不良事件数据图形工具与标准化分析的R软件包

2025-12-200
OAAI
Psychometric Properties and Interpretability of PRO-CTCAE® Average Composite Scores as a Summary Metric of Symptomatic Adverse Event Burden

心理测量属性与PRO-CTCAE®平均综合分数作为症状性不良事件负担汇总指标的可解释性

2025-10-290
OAAI
Methods for implementing and reporting the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to measure patient-reported adverse events in cancer clinical trials

实施和报告不良事件常见术语标准(CTCAE)的患者报告结局(PRO)版的方法,用于测量癌症临床试验中的患者报告不良事件。

Cancer
IF5.1
2025-10-220
OAAI
Use of patient-reported outcomes version of the common terminology criteria for adverse events in oncology clinical trials

使用患者报告结局版不良事件通用术语标准在肿瘤学临床试验中的应用

2025-09-011
OAAI
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)
2024-11-060
OAAI
TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

TP53改变使骨髓增殖性肿瘤患者发生白血病转化的风险增加,且较高分险分子突变患者的生存更差。

BLOOD
IF23.1
2024-11-050
PRE
Trial in Progress- Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

试验进行中-联盟A052101:一项关于在老年套细胞淋巴瘤患者中,作为一线治疗使用zanubrutinib进行持续与间歇维持治疗的随机III期试验

BLOOD
IF23.1
2024-11-050
PRE
Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort
2024-08-017
PRE
Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures
2023-09-285
OAAI